Co-expression of the MDR1 gene and HSP27 in human ovarian cancer

Anticancer Research

Volumn 18, Issue 4 C, 1998, Pages 2967-2971

  Schneider, J ^a,c   Jimenez, E ^a   Marenbach, K ^b   Marx, D ^b   Meden, H ^b  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^c Centro de Patologia de la Mama   (Spain)

Author keywords

Cancer; HSP27; MDR; Ovary

Indexed keywords

GLYCOPROTEIN P; HEAT SHOCK PROTEIN;

ARTICLE; BREAST CANCER; CANCER SURVIVAL; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MOLECULAR WEIGHT; MULTIDRUG RESISTANCE; OVARY CANCER; PRIORITY JOURNAL;

DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAT-SHOCK PROTEINS; HUMANS; OVARIAN NEOPLASMS; P-GLYCOPROTEIN; PROGNOSIS;

EID: 0031866351     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Mattern J and Volm M: Multiple pathway drug resistance (review): Int J Oncol 2: 557-561, 1993.
2. Johnson SW, Ozols RF and Hamilton TC: Mechanisms of drug resistance in ovarian cancer. Cancer 71: 644-649, 1993.
3. Holzmayer TA, Hilsenbeck S, Von Hoff D and Roninson I: Clinical correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small cell lung carcinomas. J Natl Cancer Inst 84: 1486-1491, 1992.
4. Izquierdo MA, van der Zee AGJ, Vermorken JB, van der Valk P, Beliën JAM, Giaccone G, Scheffer GL, Flens MJ, Pinedo HM, Kenemans P, Meijer CJLM, de Vries EGE and Scheper RJ: Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma. J Natl Cancer Inst 87: 1230-1237, 1995
5. Rubin SC, Finstad CL, Hoskins WJ, Provencher D, Federici MG, Lloyd KO and Lewis JR: Expression of p-glycoprotein in epithelial ovarian cancer: evaluation as a marker of multidrug resistance. Am J Obstet Gynecol 163: 69-73, 1990.
6. Van der Zee AGS, Hollema H, de Jong S, Boonstra H, Gouw A, Willemse PH, Zijlstra JG and de Vries EG: P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/cyclophosphamide chemotherapy. Cancer Res 51: 5195-5120, 1991.
7. Green JA, Robertson LJ and Clark AH: Glutathione S-transferase expression in benign and malignant ovarian tumors. Br J Cancer 68: 235-239, 1993.
8. Schneider J, Centeno M, Jimenez E, Rodriguez-Escudero FJ and Romero H: Correlation of MDR1 expression and oncogenic activation in human epithelial ovarian carcinoma. Anticancer Res 17: 2147-2152, 1997.
9. Sorbe B, Frakendel BO and Veress B: Importance of histologic grading in the prognosis of epithelial ovarian carcinoma. Obstet Gynecol 59: 576-582, 1982.
10. Oesterreich S, Weng CN, Qiu M, Hilsenbeck SG, Osbome CK and Fuqua SA: The small heat-shock protein HSP-27 is correlated with growlh and drug resistance in human breast cancer cell lines. Cancer Res 53: 4443-4448, 1993.
11. Whelan RDH and Hill BT: Differential expression of steroid receptors, HSP27, and pS2 in a series of drug resistant human breast tumor cell lines derived following exposure to antitumor drugs or fractionated X-irradiation. Breast Cancer Res Treat 26: 23-39, 1993.
12. Fuller RJ, Issels RD, Slosman DO, Guillet J-G, Soussi T and Polla BS: Cancer and the heat-shock response. Eur J Cancer 30A: 1884-1891, 1994.
13. Schneider J and Romero H: Correlation of P-glycoprotein overexpression and cellular prognostic factors in mammary carcinoma. Anticancer Res 75: 1117-1122, 1995.
14. Schneider J, Rubio MP, Barbazan MJ, Rodriguez-Escudero FJ, Seizinger BS, and Castresana JS: P-glycoprotein, HER-2/neu and mutant p53 expression in human gynecologic tumors. J Natl Cancer Inst 86: 850-855, 1994.
15. Germain I, Tetu B, Brisson J and Cheriau MG. Markers of chemoresistance in ovarian carcinomas. An immunohistochemical study of 86 cases. Int J Gyn Path 15: 54-62, 1996.